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Background: Positron EmissionTomography imaging studies provide evidence of reduced
dopamine function in cocaine dependent subjects in the striatum, which is correlated
with prefrontal cortical glucose metabolism, particularly in the orbitofrontal cortex. How-
ever, whether enhancement of dopamine in the striatum in cocaine dependent subjects
would be associated with changes in prefrontal cortical brain activation is unknown. One
novel class of medications that enhance dopamine function via heteromer formation with
dopamine receptors in the striatum is the selective adenosine A2A receptor antagonists.
This study sought to determine the effects administration of the selective adenosine A2A
receptor antagonist SYN115 on brain function in cocaine dependent subjects. Methodol-
ogy/Principle Findings:Twelve cocaine dependent subjects underwent two fMRI scans
(one after a dose of placebo and one after a dose of 100mg of SYN115) while perform-
ing a working memory task with three levels of difﬁculty (3, 5, and 7 digits). fMRI results
showed that for 7-digit working memory activation there was signiﬁcantly greater activa-
tion from SYN115 compared to placebo in portions of left (L) lateral orbitofrontal cortex, L
insula, and L superior and middle temporal pole. Conclusion/Signiﬁcance:These ﬁndings
are consistent with enhanced dopamine function in the striatum in cocaine dependent
subjects via blockade of adenosine A2A receptors producing increased brain activation in
the orbitofrontal cortex and other cortical regions.This suggests that at least some of the
changes in brain activation in prefrontal cortical regions in cocaine dependent subjects
may be related to altered striatal dopamine function, and that enhancement of dopamine
function via adenosine A2A receptor blockade could be explored further for amelioration of
neurobehavioral deﬁcits associated with chronic cocaine use.
Keywords: cocaine, fMRI, adenosineA2A, orbitofrontal cortex, working memory
INTRODUCTION
Cocaine dependence is a clinical disorder believed to be heav-
ily inﬂuenced by the neurotransmitter dopamine. Cocaine is an
inhibitor of dopamine transport, with acute effects of increasing
extracellular concentrations of dopamine (Bradberry et al.,2000).
In human cocaine users there is evidence that chronic effects of
cocaine result in dopamine depletion or a hypo-dopaminergic
state (Parsons et al., 1991). PET studies of cocaine dependent
subjects have shown reduced dopamine D2 receptor function
(Volkow et al., 2004). Other studies of cocaine dependent sub-
jects have shown reduced dopamine release in the striatum in
response to methylphenidate (Volkow et al., 1997), and reduced
amphetamine induced dopamine release in the striatum (Mar-
tinez et al., 2007), both of which are lower in patients who do
not respond to psychosocial treatment (Martinez et al., 2011). It
has been postulated that the reduction in the number of striatal
dopamine D2 receptors combined with a reduction in dopamine
cell activity in cocaine abusers would lead to a reduced sensitivity
to natural rewards, predisposing cocaine dependent individuals
to drug seeking as a means of temporarily providing stimulation
of this system (Volkow et al., 2003). PET studies have indicated
a signiﬁcant correlation between reduction in D2 receptor bind-
ing and reduced metabolism in the orbitofrontal cortex,cingulate
cortex, and dorsolateral prefrontal cortex (Volkow et al., 1993).
This reduction in prefrontal cortical activity may also be impor-
tant for cocaine addiction, as these brain regions are involved in
working memory,decision making,and inhibitory control,which
are impaired in cocaine dependent subjects (Moeller et al., 2002;
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Fernandez-Serrano et al., 2010; Kjome et al., 2010). Dopamine is
known to be a key neurotransmitter in frontal–striatal circuits
(Fineberg et al., 2010) and frontal–striatal connectivity has been
shown to be reduced in cocaine dependent subjects (Hanlon
et al., 2011). It is unknown whether enhancing dopamine func-
tion (directly or indirectly) in the striatum in cocaine dependent
subjects would affect prefrontal cortical brain function and the
processes subserved by the prefrontal cortex, including working
memory and inhibitory control.
AdenosineA2A receptorsinthebrainarelocalizedmainlyinthe
striatum (both dorsal and ventral; Schiffmann et al.,2007),where
they have been shown to form functional units with dopamine
receptorsknownasheteromers(Zolietal.,1993;Ferreetal.,1997).
Through heteromer formation,A2A receptor activation blocks D2
receptor-mediated decrease in excitability of the striato-pallidal
neuron,whileA2A receptorantagonistsproducetheoppositeeffect
(Ferreetal.,1993;Azdadetal.,2009).Inanimalmodelsof Parkin-
son’s disease, selective A2A antagonists alone or in combination
with dopamine agonists show antiparkinsonian activity (Kanda
et al., 2000). This mechanism is the basis for the use of selective
A2A antagonists to enhance the efﬁcacy of dopamine precursors
or agonists in Parkinson’s disease (Ferre et al.,2001). Accordingly,
clinicaltrialsoftheselectiveA2A antagonististradefyllinehavepro-
vided some evidence that A2A antagonists may be helpful in the
treatmentofParkinson’sdisease(Hauseretal.,2008);however,not
all studies with istradefylline have been positive (Fernandez et al.,
2010). Because adenosine A2A receptors are localized primarily in
the striatum, and adenosine A2A antagonists have been shown to
enhance dopamine function, selective adenosine A2A antagonists
provide a unique tool to examine the effect of enhancement of
striatal dopamine function on prefrontal cortical brain function
in cocaine dependence.
MATERIALS AND METHODS
OBJECTIVES
The objective of this study was to determine the effect of an acute
dose of a selective adenosine A2A antagonist (SYN115) on brain
activation during a working memory task in cocaine dependent
subjects. The hypothesis of the study was that SYN115 would
increase brain activation in prefrontal cortical brain regions pre-
viously associated with reduced dopamine function in cocaine
dependent subjects.
Working memory was chosen for the task as it is well doc-
umented that dopamine plays a key role in working memory
(Goldman-Rakic, 1996), and previous baseline studies of BOLD
fMRI during working memory found signiﬁcantly lower BOLD
activation in cocaine dependent subjects compared to non-drug
usingcontrols(Tomasietal.,2007;Moelleretal.,2010;Bustamante
et al.,2011).
PARTICIPANTS
Twenty-three non-treatment seeking cocaine dependent subjects
were recruited using advertisements in newspapers. After provid-
ing written informed consent, subjects underwent screening with
a physical examination, complete blood count, urinalysis, urine
pregnancy test (females), serum chemistries, and HIV test. All
subjects underwent a psychiatric interview using the Structured
ClinicalInterviewforDiagnosticandStatisticalManualforMental
Disorders, Fourth Edition (DSM-IV; First et al., 2002). Inclusion
criteria were: age 18–50years, meeting DSM-IV criteria for cur-
rent cocaine dependence and not treatment seeking. Exclusion
criteria were current psychiatric disorder (other than cocaine and
cannabisdependence)orpastpsychiatricdisorder(otherthansub-
stanceabuseordependenceorsubstance-inducedmooddisorder).
Medical exclusion criteria were any clinically signiﬁcant medical
disorder or a disorder requiring medication that could affect the
central nervous system. Subjects were excluded if they had a pos-
itive breath alcohol screen or a positive urine drug screen other
than cocaine or marijuana on the day of the scan. Subjects were
also excluded if they were pregnant, had anemia, claustrophobia,
or had any history of metal fragments in eyes or other soft tissue,
or had any clinically signiﬁcant abnormalities on structural scans
as read by a board certiﬁed radiologist (co-author L. A. Kramer).
All subjects who had positive urine drug screen for cocaine on
the day of the scan were screened by a psychiatrist for symptoms
of cocaine intoxication. No subjects had DSM-IV (American Psy-
chiatric Association, 2000) symptoms of cocaine intoxication. All
subjects had an EKG on the day of the scan prior to the ﬁrst dose
of medication,andarepeatEKGaftercompletionof thescanning.
Subjects were admitted overnight to the Clinical Research Unit of
theCenterforClinicalandTranslationalSciencesof theUniversity
of Texas Health Science Center at Houston for observation after
the scan. Vital signs and repeat EKGs were performed during the
observation period until discharge at 4:30 PM the following day.
DESCRIPTION OF PROCEDURES OR INVESTIGATIONS UNDERTAKEN
Subjects and staff performing rating scales were blinded to med-
ication received. Subjects received 5 placebo capsules 30min
before the ﬁrst fMRI session and 5 (20mg) capsules of
SYN115 180min before the second fMRI session. SYN115
[4-Hydroxy-4-methyl-piperidine-1-carboxylic acid-(4-methoxy-
7-morpholin-4-yl-benzothiazol-2-yl)-amide] (chemical structure
in Supplementary Material) is a selective adenosine A2A receptor
antagonist with 110- to 260-fold selectivity for the human A2A
receptor compared to other adenosine receptors, and 1900-fold
selectivity for the A2A receptor compared to 67 other recep-
tors, neurotransmitter transporters and ion channels (Synosia-
Therapeutics,2008).Fromstudiesinhealthycontrols,thehalf-life
of a single dose of 100mg SYN115 was 15.9h, with time to peak
blood levels of 4.1h (Synosia-Therapeutics, 2008). SYN115 was
administered under IND# 102990 (Moeller).
SCANNING SESSIONS
All subjects underwent two scanning sessions on a Philips 3T
Intera system with an eight-channel receive head coil (Philips
Medical Systems, Best, Netherlands). The Eloquence upgrade to
the Integrated Functional Imaging System-Stand Alone system
(Invivo Corporation, Orlando, FL, USA) was used for stimulus
presentation and recording of performance. Spin-echo echo pla-
nar imaging (EPI), rather than gradient-echo EPI, was used for
fMRI to avoid signal losses caused by through-slice dephasing in
regions that are affected by strong magnetic susceptibility gradi-
ents at 3T magnetic ﬁeld strength (Kruger et al., 2001; Norris
et al., 2002; Wang et al., 2004). The regions affected by strong
Frontiers in Psychiatry | Addictive Disorders May 2012 | Volume 3 | Article 44 | 2Moeller et al. fMRI of adenosine antagonist in cocaine dependence
susceptibility gradients near air-tissue interfaces include (but not
limited to) medial orbitofrontal cortex, which is a region that
was hypothesized to be activated in the current study. In addi-
tion to its advantage of eliminating signal loss, spin-echo EPI
has potentially more speciﬁc spatial localization than gradient-
echo EPI (Thulborn et al., 1997; Norris et al., 2002)a t3 T
magnetic ﬁeld strength. Our published fMRI studies (Moeller
et al., 2010; Ma et al., 2011) and other cognitive fMRI studies
using spin-echo EPI at 3T (Norris et al., 2002), have successfully
obtained signiﬁcant activation in medial orbitofrontal cortex in
addition to elsewhere throughout the cortex in predicted areas,
using similar numbers of subjects as in the current study. For
the fMRI series, images were acquired in the transverse plane
using single shot spin-echo EPI with SENSE factor=2.0, repe-
tition time=2200ms, echo time=75ms, ﬂip angle=90˚, num-
ber of slices=22, ﬁeld-of-view=240mm×240mm, in-plane
resolution=3.75mm×3.75mm, slice thickness=3.75mm, gap
between slices=1.25mm, repetitions=294, 10 dummy acquisi-
tions,run duration=10min 47s. Each subject had 2 runs in each
session, separated by 1min rest. A high-resolution T1-weighted
3D-MPRAGEscan(0.938mm×0.938mm×1mm)wasacquired
for co-registration with the fMRI scans, and FLAIR and T2-
weighted scans were also acquired that were read by a radiologist
(co-author L. A. Kramer) on all subjects to rule out incidental
brain abnormalities.
fMRI BEHAVIORAL PROTOCOL
The immediate memory task/delayed memory task (IMT/DMT)
block-designfMRIprotocol(Doughertyetal.,1998;Moelleretal.,
2010; Ma et al., 2011) was used as the working memory test. The
IMT and DMT are delayed-matching-to-sample tasks. In both
IMT and DMT, each stimulus consists of a horizontal string of
numbers (e.g., 42563) that is displayed in black font on white
backgroundfor0.5s,followedbyaninter-stimulusinterval(blank
white screen) of 0.5s. Thus, the rate of stimulus presentation is
1s −1. In DMT, the target and probe stimuli are separated by dis-
tracter stimuli, consisting of a string of all zeros (e.g., 00000) that
is repeated three times at the same rate and duration as the target
and probe stimuli. Thus, in DMT, the memory delay between the
end of the target stimulus and beginning of the probe stimulus is
3.5s. The IMT is a control condition to control for non-speciﬁc
featuresof theexperimentaldesign.InIMT,therearenodistracter
stimuli, and thus the memory delay between target and probe is
0.5s. A non-salient stimulus consisting of all ones (e.g., 11111)
is presented once after each DMT trial and four times after each
IMTtrial.Thereforethesumof thedistracterstimuliandthenon-
salient inter-trial stimuli is the same (four) during DMT and IMT
conditions,andhencethenumberoftrialsissame(seven)forIMT
blocks and DMT blocks. In both IMT and DMT, the probability
of a match and the probability of a catch are both 50%. In a catch,
the probe differs from the target in only one of the digits. Sub-
jects were instructed to press a button using the right index ﬁnger
only when the probe matches the target. The A  score (Donald-
son, 1992) was used as an accuracy measure. The A  score ranges
from 0.5 to 1.0,corresponding to chance to perfect discriminabil-
ity, respectively. The IMT/DMT fMRI protocol is a block design.
There are 12 blocks alternating between IMT and DMT within
each run. The number of digits in the stimulus string can be 3, 5,
or7digitsandisheldconstantwithineachblock.Thedigit-length
conditions represent three different levels of digit-length load. All
digit-length conditions are presented within each run,in counter-
balanced order between runs and subjects. The duration of each
blockis42.5s;thereare10srestbetweenblocksand20srestatthe
beginningof eachrun.Allsubjectscompletedtrainingina“mock”
scanner while listening to a recording of MRI sounds prior to the
ﬁrst MRI session.
fMRI PROCESSING
For each voxel during an fMRI run, the AFNI software (Cox,
1996) module“3dDespike”was used to automatically replace any
extremeoutlierintherawdatabythemeanof itstwoneighboring
time points. Extreme outlier was deﬁned as an MRI signal value
greater than 12 standard deviations from the mean (i.e., greater
thantwicetheaveragerangeof thetimeseries(Tippett,1925).The
imagesunderwentfurtherpreprocessingusingStatisticalParamet-
ric Mapping (SPM5) software from the Wellcome Department of
Cognitive Neurology, London, UK, implemented in Matlab 7.1
(MathWorks Inc.,Sherborn,MA,USA).After slice-timing correc-
tion, the fMRI series was realigned to correct head motion. Runs
with head motion greater than one voxel (3.75mm translation)
or 3.75˚ rotation were eliminated from the analysis. For each sub-
ject, the ﬁrst run without excessive motion and that met criteria
for greater than chance accuracy (i.e., with A  score greater than
0.5) in the majority of blocks was included in the analysis. The
3D-MPRAGE image was coregistered to the mean fMRI image
and then transformed to Montreal Neurological Institute (MNI;
Mazziotta et al., 2001) atlas coordinates using the SPM5 Normal-
ize module. This transformation was applied to the fMRI images
to convert them to MNI coordinates, and the fMRI images were
resliced to 2mm isotropic and smoothed with a Gaussian ﬁlter of
8mm isotropic full width at half maximum.
ETHICS
All subjects provided written informed consent prior to partici-
pation in this study. This study was approved by the Committee
for the Protection of Human Subjects (CPHS), which is the Insti-
tutional Review Board for the University of Texas Health Science
Center at Houston.
STATISTICAL METHODS
fMRI statistical parametric mapping analysis
Statistical analysis of the fMRI data was conducted using SPM5.
The fMRI time series was high-pass ﬁltered with a cut-off period
of 330s determined by Fourier transformation of the experi-
mental model, which showed that the experimental signal was
preserved at 330s, but that shorter cut-off periods would elimi-
natemostof thesignalfromtheexperimentalcondition.TheIMT
and DMT blocks for each digit condition were modeled by box-
car functions convolved with the SPM5 hemodynamic response
function.Theparametersforeachconditionwereestimatedusing
the General Linear Model at each voxel without global normal-
ization. Activation for each digit-length condition was deﬁned as
the contrast of DMT minus IMT parameter estimates for that
condition (i.e., 3-digit DMT minus 3-digit DMT; 5-digit DMT
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minus 5-digit IMT, and 7-digit DMT minus 7-digit IMT). For
each subject, a contrast image of SYN115 minus placebo activa-
tion was entered into the SPM5 second-level (Random Effects)
analysis with a one-sample t-test for each digit-length activation
condition. The cluster-deﬁning threshold was voxel t =3.0. All
cluster P values that are reported for the fMRI analysis in this
paper were corrected for multiple comparisons by SPM5 to con-
trol the family wise error (FWE) rate to be less than 0.05 (Friston
et al., 1994). In addition, the reported p values were further cor-
rected to account for two tails (i.e., SYN115 greater than Placebo,
and SYN115 less than Placebo). Approximate anatomical labels
for regions of activation were determined using the Anatomical
Automatic Labeling (Tzourio-Mazoyer et al., 2002) toolbox for
SPM and direct inspection of the activation clusters. The mean
activation across all voxels within a cluster was computed using
MarsBaR Toolbox.
Statistical Analysis of Behavioral and Cardiovascular Data
Statistical analysis of behavioral and cardiovascular data used
repeated measures analysis of variance (ANOVA) after graphical
inspection of the residuals indicated normal distributions. Sys-
tolic and diastolic blood pressure and heart rate were compared
between pre- and post-dose for placebo and SYN115. Data col-
lected at the time of estimated peak blood concentration (4h)
for SYN115 was used as a comparison to data collected at 2h post
placebobecause4hpostplacebodatawasnotobtained.Behavioral
performanceduringthescanwasanalyzedwiththeSAS9.2GLIM-
MIX procedure implementation of repeated measures ANOVA,
and correlations were computed using Spearman non-parametric
CORR procedure.
RESULTS
SCREENING AND DEMOGRAPHIC RESULTS
Of the 23 subjects who provided written informed consent and
met initial screening criteria, 3 subjects withdrew from the study
prior to receiving SYN115 due to claustrophobia in the MRI
scanner, and 1 subject withdrew due to being physically uncom-
fortable in the scanner related to a prior hip injury. Two subjects
were excluded due to excessive head motion, one subject was
excluded due to artifacts in the fMRI series, three subjects were
excluded due to clinically signiﬁcant abnormalities on structural
MRI scans, and one subject was excluded due to discovery of a
previously unreported diagnosis of Bipolar Disorder. All exclu-
sion decisions were conducted blind to fMRI results for those
subjects.
Twelve cocaine dependent subjects were included in the ﬁnal
analysis. The mean age of the subjects who were included was
39.7±5.3years with a range of 29–49. Eleven of these subjects
were male and 1 was female. All subjects were right handed. Nine
of the subjects had a positive urine drug screen for cocaine, two
subjects had a positive urine drug screen for both cocaine and
marijuana,andonesubjecthadanegativeurinedrugscreenatthe
time of the scan. Subjects reported cocaine use for an average of
17.3±6.6years (ranging from 8 to 28years). Last use of cocaine
was 3.5±5.0days prior to the scan (ranging from 0.8 to 19days).
None of the subjects had symptoms of cocaine intoxication at the
time of the scan. All subjects had zero breath alcohol levels at
the time of the scan. Eight of the 12 subjects were daily cigarette
smokers, smoking 8.6±7.6 cigarettes per day (range 0–20). Five
of thesesubjectswereadministeredanicotinepatchtoavoidnico-
tine withdrawal and did not smoke on the day of the scan. For
regular cigarette smokers, the last nicotine (other than nicotine
patch)priortothescanwas4±5hpriortothescan(range1–13).
No subjects consumed caffeine on the morning of the scan.
CARDIOVASCULAR EFFECTS
No clinically signiﬁcant adverse events were reported by the sub-
jects. Vital signs pre and post placebo and SYN115 are shown in
Table 1.
Systolic blood pressure showed an effect of time after both
placebo and SYN115 administration (F =13.74, p =0.003), and
a trend effect for an overall difference between drugs (SYN115
vs. placebo; F =4.1, p =0.068), but no signiﬁcant drug by time
interaction (F =0.077, p =0.787). For diastolic blood pressure
there was no signiﬁcant effect of time (F =0.278, p =0.61), but
there was a signiﬁcant overall difference between drugs (F =7.42,
p =0.02). There was no signiﬁcant drug by time interaction
(F =0.019,p =0.892).Forheartrate,therewasasigniﬁcanteffect
of time (F =6.38, p =0.028), drug (F =7.66, p =0.018), and a
drug by time interaction (F =18.24, p =0.001), with heart rate
decreasingbetweenbaselineandpostplaceboandremainingstable
between baseline and post SYN115.
EFFECTS OF SYN115 ON IMT/DMT PERFORMANCE
A mixed effects model (Proc GLIMMIX; SAS v. 9.2) evaluated
IMT and DMT separately based on A  score (a metric of signal
discriminability and correct response execution) as a function of
two within-subject factors: drug and digit-length. Analyses exam-
ined main effects, polynomial trends, and interactions. Observed
values are displayed in Figures 1A,B.
For both IMT and DMT, initial model ﬁtting identiﬁed linear
and quadratic components for digit-length but failed to ﬁnd any
reliable relations for drug (Table 2).
Inspectionoftheinteractionsbetweenthelineartrendfordigit-
lengthanddrug,aswellasforthequadratictrendsfordigit-length
anddrug,failedtoincrementthepredictionofthemodel(Table 3)
for either IMT or DMT. The model predicting IMT A  score indi-
cated that for every two additional digits in digit-length, A  score
decreased by 0.040 points.
ThisdecreaseinA  scorewasfurtheracceleratedby0.010points
for every two additional digits in digit-length (Figure 1A). Simi-
larly, the model predicting DMT performance indicated that for
every two increments in digit-length, A  score decreased by 0.060
points. This decrease in A  score was further accelerated by 0.010
Table 1 |Vital signs predose and post-dose for placebo and SYN115
(mean±standard deviation).
Pre Placebo Post
Placebo
Pre SYN115 Post
SYN115
Systolic B/P 106.9±11.6 114.2±8.8 111.2±8.2 119.9±16.0
Diastolic B/P 70.9±10.1 71.9±9.0 74.1±6.9 74.7±8.1
Heart rate 72.9±10.2 63.8±4.9 64.5±6.7 64.8±4.7
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FIGURE1|( A )IMT A’ as a function of digit-length and drug condition with
95% conﬁdence intervals. (B) DMT A’ as a function of digit-length and drug
condition with 95% conﬁdence intervals.
points for every two additional digits in digit-length (Figure 1B).
In summary, digit-length exerted systematic effects on perfor-
mance,measuredbyA ,buttherewerenoeffectsofdrugcondition
or drug×digit-length interactions.
fMRI RESULTS
SPM5second-level(Randomeffects)analysisresultedinnosignif-
icant clusters in which placebo produced greater activation than
SYN115 for any (3, 5, or 7) digit-length condition (two-tailed
FWE-corrected cluster p >0.05). For 3-digit, and 5-digit condi-
tions, no signiﬁcant clusters were found in which SYN115 pro-
duced greater activation than placebo (two-tailed FWE-corrected
cluster p >0.05). For the 7-digit condition, there was a cluster
of 362 voxels in which SYN115 produced signiﬁcantly greater
activation(two-tailedFWE-correctedclusterp =0.010)compared
to placebo (Table 4; Figure 2). The signiﬁcant cluster was found
in portions of left lateral orbitofrontal cortex, left insula, and left
superior and middle temporal poles.
Table 2 | Results of statistical analysis of behavioral data model without interactions.
Effect Type III tests of ﬁxed effects
IMT DMT
Num DF Den DF F value Pr>F Num DF Den DF F value Pr>F
Digit-length 1 57 37 .09 <0.0001 1 57 77 .40 <0.0001
Digit-length*digit-length 1 57 8.89 0.0042 1 57 6.87 0.0112
Drug 1 57 0.27 0.6044 1 57 0.47 0.4946
Table 3 | Results of statistical analysis of behavioral data model with interactions.
Effect Type III tests of ﬁxed effects
IMT DMT
Num DF Den DF F value Pr>F Num DF Den DF F value Pr>F
Digit-length 1 55 37 .09 <0.0001 1 55 77 .40 <0.0001
Digit-length*digit-length 1 55 8.89 0.0043 1 55 6.87 0.0113
Drug (syn 115 v. Placebo) 1 55 1.18 0.2828 1 55 0.96 0.3323
Digit-length*drug 1 55 0.01 0.9377 1 55 0.19 0.6644
Digit-length*digit-length*drug 1 55 2.05 0.1580 1 55 0.26 0.6103
Table 4 | SPM5 random effects comparison of SYN15 vs. placebo for 7-digit working memory activation within 12 cocaine dependent subjects.
Comparison Two-tailed
FWE-corrected
cluster p
Number of
voxels in
cluster
Mean difference in activation
between doses across all
voxels in cluster (% whole
brain BOLD; ±90% CI)
Relative maximal
voxel t (11 d.f.)
XY Z Location
SYN115>placebo p =0.010 362 0.8631 (0.2549) 5.68 −34 16 −18 Left lateral orbital cortex
Placebo>SYN115 p >0.05 NS
Signiﬁcance criterion=family wise error (FWE) corrected two-tailed cluster p<0.05. NS, not statistically signiﬁcant.Within each signiﬁcant cluster, the relative max-
imal voxel t value and approximate anatomical location within 3mm radius are listed. X,Y, and Z are MNI standard space coordinates (mm) of the relative maximal
voxel in the cluster. Negative X=Left hemisphere. d.f., degrees of freedom. Smoothness of residual ﬁeld FWHM=[10.6 10.1 8.6]mm. Search volume=154244
voxels=1238.8 resolution elements (resels). Voxel size=[2 2 2]mm.
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FIGURE 2 | Results of the within-group analysis.The cluster of voxels
(fromTable 2) that showed signiﬁcantly greater activation after SYN115
compared to placebo within the SYN group is depicted in color overlaid on
a montage of slices from the standard MNI brain in gray.The slices
progress from inferior slices in the left upper corner of the window to
superior slices in the right lower corner of the window.The number in
white below each slice is the MNI Z coordinate in mm for that slice.The
left hemisphere is on the reader’s left-hand side of each slice.The color
scale is in the right lower corner of the window and is in units of the t
statistic.
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DISCUSSION
To our knowledge,this is the ﬁrst study to examine the effects of a
selective adenosine A2A receptor antagonist on brain function in
cocaine dependent subjects. The main ﬁnding is that there was a
signiﬁcant increase in brain activation in left lateral orbitofrontal
cortex,leftinsula,andlefttemporalpoleafterSYN115comparedto
placebo. Prior imaging studies have shown evidence of connectiv-
ity between the striatum and insula (Postuma and Dagher, 2006),
which is consistent with neuroanatomical studies in non-human
primates (Chikama et al., 1997). Likewise, studies in non-human
primates have shown reciprocal connections between the tem-
poral pole and orbital prefrontal cortex (Kondo et al., 2003).
The temporal pole, insula, and orbitofrontal cortex comprise the
insulo-orbito-temporopolar component of the paralimbic brain
as described by Mesulam and Mufson (1982), which is thought
to be important in the integration between external stimuli and
internal states (Chabardes et al., 2002).
Cocaine dependent subjects have been shown to have altered
brain function in paralimbic regions associated with cocaine
craving (Kilts et al., 2001; Risinger et al., 2005).
The increase in brain activation after SYN115 was not accom-
panied by a signiﬁcant change in performance on the working
memory task. This ﬁnding is not uncommon in fMRI research of
cognition using a single dose of medication. In a study by Tomasi
etal.(2011)asingledoseof 20mgof methylphenidateproduceda
signiﬁcant increase in brain activation in healthy controls in pari-
etal and prefrontal cortical regions but had no signiﬁcant effect
on performance of a working memory task. Likewise, acute doses
of the cholinesterase inhibitor galantamine did not produce a sig-
niﬁcant behavioral effect on a facial recognition task in patients
with Alzheimer’s disease but did produce a signiﬁcant increase in
brain activation (Goekoop et al., 2006). In another study by Ye
et al. (2011) an acute dose of pramipexole did not signiﬁcantly
affect performance on a monetary incentive delay task but did
produce a signiﬁcant increase in brain activation in the nucleus
accumbens. These studies support brain activation as being more
sensitive to effects of single doses of medication than cognitive
performance.
Signiﬁcantdifferenceswereonlyobservedontrialswith7-digit
stimuli. This may be due to the relatively few errors in the 3-
and 5-digit stimuli, creating a ceiling effect on medication related
changes in both performance and brain activation.
Based on the work of Volkow et al. (1993) showing a signiﬁ-
cant reduction in orbitofrontal metabolism in cocaine dependent
subjects, which was correlated with reduced striatal D2 receptor
availability, the results of the current study are consistent with
SYN115 enhancing dopamine function in the striatum leading
to increased brain activation in orbitofrontal cortex and other
brain regions. In the study of Volkow et al. (1993), left and right
orbitofrontal cortex were combined as a region of interest show-
ing a signiﬁcant correlation with striatal D2 receptor availability.
The current study found a signiﬁcant increase in left orbitofrontal
cortical activation. This ﬁnding could be related to the task
used in the current study, as prior studies have shown a domi-
nance of left hemisphere in verbal working memory (Binder and
Urbanik, 2006; Oztekin et al., 2009) and number processing tasks
(Dehaene et al., 2003). Other studies have shown that medication
that enhances dopamine can affect brain activation in prefrontal
regions without signiﬁcant activation in the striatum. During a
working memory task, methylphenidate signiﬁcantly increased
brain activation in prefrontal regions without a signiﬁcant acti-
vation effect on the striatum in healthy controls (Tomasi et al.,
2011),andmethylphenidateincreasedbrainactivationintheante-
rior cingulate without signiﬁcantly affecting striatal activation in
cocaine users performing a salient cognitive task (Goldstein et al.,
2010).
The effects of dopamine enhancement on activation in pre-
frontal brain regions without signiﬁcantly altering activation in
the striatum may be related to the ﬁndings of previous preclinical
studiesshowingthatenergymetabolismchangesaregreatestatthe
site of increased synaptic activity, instead of the site of increased
spiking activity (Buxton, 2009).
LIMITATIONS
A limitation of this study is that in order to avoid carry over
effects of SYN115, all subjects received placebo on the ﬁrst fMRI
scan and SYN115 on the second fMRI scan. This raises the pos-
sibility that some of the differences in brain activation could be
related to practice or time of day effects. However, the increased
brain activation after SYN115 occurred in a relatively localized
brain region, which overlaps with regions known to be correlated
withreducedD2receptoravailabilityincocaineabusers.Thissug-
gests that at least some signiﬁcant portion of the brain activation
resultscanbeattributedtotheacuteeffectsof SYN115.Bearingin
mind this limitation,the observed brain activation changes in this
study suggest that enhancing dopamine function in the striatum
increases brain activation in the orbitofrontal cortex in cocaine
dependent subjects via effects of the A2A antagonist SYN115. The
lateral orbitofrontal cortex is associated with executive control of
behavior, which is critical in the initiation and maintenance of
addictions (Volkow et al.,2011).
Data from clinical trials support the use of dopamine enhanc-
ing medications for cocaine dependence. Medications showing
some evidence of reduction of cocaine use in clinical trials
include those that inhibit dopamine reuptake or metabolism
(e.g., bupropion, disulﬁram; Carroll et al., 2004; Poling et al.,
2006), replenish dopamine stores (e.g., levodopa; Schmitz et al.,
2008), or indirectly enhance dopaminergic function via effects
on dopamine release (e.g., dextroamphetamine; Grabowski et al.,
2004) and methamphetamine (Mooney et al., 2009). The adeno-
sine A2A receptor may be a target for treatment of cocaine depen-
dence given its involvement in critical brain regions affecting
dopamine function (Ferre et al., 2007). Based on the approach
of dopamine enhancement as a potential treatment for cocaine
dependence (Moeller et al., 2008), adenosine A2A antagonists
could be investigated further as a potential treatment for cocaine
dependence.
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